-+ 0.00%
-+ 0.00%
-+ 0.00%

Contineum presents PIPE-791 pulmonary fibrosis data at ATS 2026 conference

PUBT·05/11/2026 20:06:34
Listen to the news
Contineum presents PIPE-791 pulmonary fibrosis data at ATS 2026 conference
  • Contineum Therapeutics flagged two upcoming scientific poster presentations on lead investigational candidate PIPE-791 at ATS 2026 in Orlando, scheduled for May 15-20, 2026; results will be presented in the future.
  • One poster is set to compare PIPE-791 with a rival LPA1 antagonist, focusing on differences in lung exposure and vascular effects, positioning the program against a key competitor in pulmonary fibrosis research.
  • A second poster is slated to show preclinical evidence that blocking LPA1 with PIPE-791 can reduce cell death in lab-based lung epithelial models, supporting the drug’s proposed protective effect in fibrotic disease biology.
  • Both posters are scheduled for May 18, 2026, during a pulmonary fibrosis session, keeping near-term investor focus on translational data rather than clinical readouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605111605BIZWIRE_USPR_____20260511_BW897086) on May 11, 2026, and is solely responsible for the information contained therein.